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ABSTRACT:
Labetelol causes significant maternal and fetal metabolic effects in
pregnant shep (Yeleswaram .t aL, J. Pharmacol. Exp. Ther. 262,
683-691 (1992)). This study was undertaken to investlate the con-
tributlon of skeletal muscles In the development of metabolic aci-
dosis Induced by labetalol and to explore the Involvement of active
metaboifte(s) using conscious, chronically instrumented adult non-
pregnant ewes. Following a 100 mg iv bolus, the disposition of
Iabetalol was similar to that observed in pregnant sheep. The effects
of IabetalOl Included hypotenslon, reflex tachycardla, a significant
increase In femoral blood flow, hyperglycemia, lactic acidosis, and
increased hind limb oxygen consumption. The arterloverious flux of
labetalol, glucose, lactate, and oxygen across the hindlimb was
calculated using the Fick principle. The net output of lactate from
the hindquarter over 12 hr following drug administration was calcu-
lated to be 6.25 ± 1.35 g (0.07 ± 0.015 mol). Glucuronidatlon,
sulfatlon, and oxidative metabolism of Iabetalol were studied using
urine and bile samples. The cumulative urinary excretion of IabetalOl
as unchanged drug, glucuronide and sulfate was found to be 1.61 ±
0.38, 11.46 ± 2.83, and 1.47 ± 0.74% of the dose, respectively. Using
GC-mass selective detection, the presence of 3-amino-1-phenylbu-
tane (3-APB), a close congener of amphetamine, In urine and bile
samples was established. The cumulative excretion of 3-APB in urine
represents 0.044 ± 0.016% of the dose. Pharmacokinetic analysis
shows the apparent elimination half-life of the metabOlftS to be 13.5
± 3.8 mm. Conjugates of 3-APB were also found in the bile and urine.
The close similarity between the reported metabolic effects of am-
phetamlne and that observed following labetalol administration may
suggest a possible involvement of 3-APB in the mediatIOn of IabetalOl
pharmacodynamics.
Labetalol, a combined a- and fl-adrenergic blocker, is used as
an antihypertensive, especially in the management of pregnancy-
induced hypertension. The compound has two chiral centers (fig.
1 ) and is marketed as a racemic mixture of all four isomers,
which are present in roughly equal proportions (1). Recently, we
have observed that labetalol causes significant metabolic effects
in pregnant sheep, including pronounced maternal and fetal
lactic acidosis (2). However, the mechanism(s) involved in those
metabolic effects and the site of release of lactate were not clear.
Further, the observed metabolic effects showed poor correlation
to plasma labetalol concentration, suggesting the possibility of
involvement of an active metabolite. Labetalol undergoes exten-
sive metabolism but the metabolic pathways are not fully under-
stood. However, it was recently reported that it undergoes N-
dealkylation to yield 3-APB’, a close congener of amphetamine,
and its hydroxylated derivative (3). This study was undertaken
to investigate the metabolism and pharmacodynamics of labe-
talol in adult nonpregnant sheep with a view to understand the
role of skeletal muscle and other carcass components in the
release of lactic acid, as well as to explore the involvement of
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1 Abbreviations used are: 3-APB, 3-amino-1-phenylbutane; HFBA, heptafluoro-
butyric anhydride; GC-MSD, gas chromatography with mass selective detection;
AUC. area under the concentration-time curve; AUMC, area under the first moment
curve.
active metabolites of labetalol in the mediation of labetalol-
induced metabolic effects.
Materials and Methods
Injectable labetalol HC1 (5 mg/ml) (Trandate) was purchased from
the Pharmacy Department, Grace Hospital (Vancouver, British Colum-
bia). Ethyl acetate (HPLC grade), toluene and n-hexane (CC grade) were
obtained from Caledon Laboratories (Georgetown, Ontario, Canada).
HFBA and triethlyamine (sequanal grade) were from Pierce (Rockville,
IL). Glucose oxidase and lactate dehydrogenase assay kits were obtained
from Sigma Chemical Company (St. Louis, MO). The enzyme prepara-
tions used in conjugate analysis (9-glucuronidase and arylsulfatase), Tris
base, and Tris HO were obtained from Sigma Chemical Co. All other
chemicals were of analytical grade and obtained from BDH Canada
(Toronto, Ontario, Canada). Distilled water ofhigh purity (HPLC grade)
was produced onsite using a Milli-Q#{174}water system (Millipore, Missis-
sauga, Canada).
Catheterization Procedures. Nonpregnant Dorset or Suffolk breed
ewes aged 5-1 1 years were used in the study. Ethical approval was
obtained from the Animal Care Committee of the University of British
Columbia. Further, the procedures used in the study conformed to the
guidelines of the Canadian Council on Animal Care. The ewes were
sedated with intravenous sodium pentothal (1-1.5 g) and anesthetized
with a mixture of halothane (1-2%), nitrous oxide (60%), and oxygen.
Silicone rubber catheters (Dow Coming, Midland, MI) were implanted
in the femoral artery and vein in one limb while a 6R-series transit-time
blood flow transducer (Transonic Systems Inc., Ithaca, NY) was placed
on the femoral artery of the other hind limb. An abdominal incision to
the right of the umbilicus was made to gain access to the gallbladder,
where a catheter was placed to allow bile collection. The catheters were
exteriorized, tunneled subcutaneously through an incision on the flank,
and secured in a denim pouch. The catheters were filled with heparinized
saline and capped when not in use. Ampicillin (500 mg) and gentamicin










FIG. 1 . Oxidative metabolism of labetalol.
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Not exhaustive; dotted lines indicate potential pathways; asterisk indicates chiral center; structure of amphetamine is included to illustrate the
close similarity to 3-APB; partly from ref. 3.
the following 4 days. The ewes were allowed to recover for at least 5 days
before they were used in the experiments. Just before the beginning of
each experiment, a Foley catheter was inserted for total urine drainage.
Dosing and Sample Collection. Five animals were used in this study.
A 100 mg dose of labetalol was administered as an intravenous bolus.
Blood samples (3 ml) for the quantitation of labetalol, glucose, and
lactate were obtained from femoral artery and vein at -30, -15, 3, 10,
15, 20, 30, 45, and 60 mm, every 30 mm until 4 hr and then at 5, 6, 8,
10, 12, and 24 hr following drug administration. Samples (0.5 ml) for
blood gas analysis(pH, base excess, p02, pCO2, hemoglobin content, and
percent oxygen saturation) were also obtained simultaneously. Urine was
collected continuously and aliquots (10 ml) corresponding to fixed
intervals (0-30 mm, 30-60 mm, and then every hour until 6 hr, and
then at 6-8, 8-10, 10-12, and 12-24 hr following drug administration)
were retained. Bile samples were obtained from only two of the animals
(E#6l7 and 248). Although continuous draining of bile will deplete the
physiologically essential components (e.g. bile salts), samples were ob-
tamed over discrete half-hour intervals by gravity-assisted draining at 30
mm, and 2, 4, and 10 hr following labetalol administration.
Physiological Monitoring. Arterial and venous pressures were moni-
tored continuously using disposable DTX pressure transducers (Spec-
warned, Oxnard, CA). Heart rate was obtained using cardiotachometers
(model 9857; Sensormedics, Anaheim, CA), and femoral blood flow was
measured by a Transonic flowmeter (model 201 D; Transonic Systems,
Inc., Ithaca, NY). The pressure, heart rate, and flow outputs were
continuously monitored on a polygraph recorder (Beckman R-7l I, Sen-
sormedics, Anaheim, CA), as well as processed on an on-line computer-
ized data acquisition system (2) for at least 2 hr before and 24 hr after
drug administration.
Analytical Procedures. Blood pH, p02, and pCO2 were determined
using an IL 1306 pH/blood gas analyzer (Allied Instrumentation Labo-
ratory, Milan, Italy), which also calculates base excess and bicarbonate,
whereas hemoglobin concentration and oxygen saturation were measured
using a Hemoximeter (Radiometer, Copenhagen, Denmark). Oxygen
content was calculated as hemoglobin concentration (g/lOO ml) . oxygen
saturation (%) . 0.0139. Arterial and venous blood glucose and lactate
concentrations were measured in duplicate using glucose-oxidase and
lactate-dehydrogenase enzymatic assay kits, respectively (Sigma Chemi-
cal Company, St. Louis, MO). Racemic labetalol concentrations in
arterial and venous plasma, urine, and bile samples were determined in
duplicate using a sensitive microbore HPLC method with fluorescence
detection (4).
Plasma, urine, and bile samples were analyzed for 3-APB, an oxidative
metabolite of labetalol (3) by a highly specific and sensitive GC-MSD
method developed in this laboratory (5). Briefly, 1 ml samples of urine,
bile, or plasma were extracted with 6 ml n-hexane after the addition of
100 ng of internal standard (l-methyl-2-phenoxyethylamine; Aldrich
Chemical Company, Milwaukee, WI) and 300 Ml of 5 N sodium hydrox-
ide, by tumble mixing for 5 mm. The organic layer was then separated
and dried in an automatic Speed Vac concentrator (model AS290,
Savant, Farmingdale, NY) at ambient temperature. The samples were
then reconstituted with a 0.0125 M solution of triethylamine in toluene
and treated with 20 d of HFBA at 55C for 1 hr and then cooled to
room temperature. The excess derivatizing reagent was removed by
treating the samples first with 0.5 ml distilled water and then with 0.5
ml 4% ammonium hydroxide solution with a 30-sec vortex mixing after
each addition. The samples were centrifuged at l000g for 3 mm, the
organic layer was transferred to autosampler vial inserts, and 1 Ml was
injected into a Hewlett-Packard (Avondale, PA) Series II GC equipped
with a 7673 autoinjector, model G1O3OA chemsiation (DOS Series) and
connected to a 5971 A MSD. A cross-linked fused-silica capillary column
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(Ultra2; Hewlett-Packard) and a wide bore (4 mm i.d.) borosilicate glass
inlet liner with a silanized glass wool plug were used for chromatography.
Helium was used as the carrier gas at a flow rate of 30 cm/sec. The oven
temperature was programmed to increase at 15#{176}C/mmfrom an initial
temperature of 100#{176}Cto 200#{176}Cand then at 30#{176}C/mmto 280’C. The
inlet temperature was maintained at 200#{176}C.Electron-impact ionization
ofthe analyte was achieved in the MSD using a 70 eV ionisation energy.
Identification of 3-APB in the biological fluids was accomplished in the
positive ion scan mode using an authentic standard (Fluka AG, Federal
Republic of Germany), whereas quantitation was performed in the
selected ion monitoring mode using two groups of two ions each: m/z
347.4 (Mt) and 134 (internal standard derivative) and m/z 345.4 (M)
and 132 (3-APB derivative). The assay was linear in the range of 0.5-
1000 ng 3-APB, with intrasample coefficients ofvariation less than 12%
in all cases. The minimum quantitation limit of the assay was 0.5 ng/
ml, which is equivalent to 2 pg injected.
Glucuronide and sulfate conjugates of labetalol and 3-APB were
determined following enzymatic hydrolysis using the general procedures
described by Brashear et al. (6). Urine (50-100 l for labetalol conjugates
and 1 ml for 3-APB conjugates) and bile (250 zl for labetalol conjugates
and 1 ml for 3-APB conjugates) samples were incubated overnight with
either 9-glucuronidase from bovine liver or arylsulfatase from Aerobacter
aerogenes, after adjusting the sample pH to 5.0 (for 3-glucuronidase)
using 0.2 M sodium acetate buffer or to pH 7.5 (for arylsulfatase) using
0.05 M Tris buffer. Glucuronide or sulfate conjugate concentrations in
the biological fluids are expressed as the difference between the total
(following incubation) and free (preincubation) concentrations (of labe-
talol or 3-APB).
Data Analysis. The weighting factor for the plasma labetalol concen-
tration data was chosen by the method of Albert el al. (7), and
PCNONLIN (version 3.0) was used to fit the concentration-time data
to obtain the most appropriate exponential and an estimate of , the
terminal elimination rate constant, corresponding to that exponential.
AUC and AUMC were determined by trapezoidal approximations. Es-
timates of  and AUMCI.IU,.,, were made as ICI.IU,1131 and it-last
. C,./$ + C,4j2), respectively (8). The terminal elimination half-life
was calculated as [0.693/a], total body clearance as [Dose/AUC], mean
residence time as [AUMC/AUC], volume ofdistribution as [Dose/(AUC
. i9)], and the nonparametric steady-state volume ofdistribution as [Dose
. AUMC/(AUC)2] (9). The changes in blood gas parameters, glucose,
and lactate concentrations and fluxes were analyzed for statistical signif-
icance by Fisher’s least square difference using SPSS/PC+ program
(SPSS, Inc., Chicago, IL). The estimates of pharmacokinetic parameters
were compared with the values obtained in pregnant sheep by two-tailed
Student’s t test. The significancelevel used wasp < 0.05. Unless otherwise
specified, values are expressed as mean ± SEM.
Results
Disposition and Metabolism. The mean weight of the ewes
(n = 5) used in the study was 74.9 ± 4.0 kg. The disposition of
labetalol in sheep arterial plasma following a 100 mg iv bolus
administration is shown in fig. 2. The decline of labetalol con-
centration was best described by a triexponential equation of the
type PeT’ + Ae#{176}’+ Be’. The weighting factor chosen was 1/
C2. The mean total body clearance was 29.00 ± 2.67 ml/min/
kg, whereas the mean terminal elimination half-life was 2.41 ±
0.30 hr. Mean residence time was I .85 ± 0.09 hr. The volume
of distribution and the nonparametric steady-state volume of
distribution were 3.22 ± 0.3 1 and 6.9 1 ± 1 . 13 liter/kg, respec-
tively. Excretion of labetalol in urine and bile as free drug
(unchanged labetalol) and as glucuronide and sulfate was studied
to assess the contribution of these pathways in the overall dim-
ination of labetalol. Cumulative urinary excretion of unchanged
labetalol accounted for 1 .61 ± 0.38% of labetalol dose, whereas
the glucuronide and sulfate conjugates accounted for I 1 .46 ±
2.82 and 1.47 ± 0.74% of the dose respectively (fig. 3). Concen-
TIME (h)
FIG. 2. Disposition oflabetalol in adult sheep plasma (concentrations









FIG. 3. Cumulative urinary excretion oflabetalol and its conjugates
(mean ± SEM).
(A) Cumulative amount excreted. (B) Percentage of labetalol dose
corresponding to the total amounts excreted.
trations of labetalol and its conjugates in the bile are shown in
fig. 4.
Plasma, urine, and bile samples were also analyzed for the
presence of 3-APB (fig. 1), an oxidative metabolite of labetalol.
Although 3-APB could not be detected in the plasma samples,
its presence in urine and bile samples was established by GC-
MSD using an authentic standard (5). The urinary excretion
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FIG. 5. Urinary excretton of3-APB (mean ± SEM).
(A) Cumulative excretion. (B) Rate ofexcretion.
excretion of 3-APB over 24 hr was 43.76 ± 16.4 zg, representing
0.044 ± 0.016% ofthe dose. The terminal slope of 3-APB urinary
excretion rate plot (0. 123 ± 0. 14 hr’) was not significantly
different from that of labetalol in plasma (0. 134 ± 0. 1 3 hr’)
(paired t test), implying that the elimination rate constant of the
metabolite (KM) is much higher than that ofthe parent drug (K)
(9). Application of the method of residuals provided an estimate
of the apparent elimination half-life of the metabolite equal to
FIG. 6. Excretion of3-APB and its conjugates in urine and bile.
(A) Urine (amount) (E#l05). (B) Bile (concentration) (E#248).
13.5 ± 3.8 mm. Evidence for glucuronidation and sulfation of
3-APB was also obtained (fig. 6). Although only the glucuronide
of the metabolite could be detected in urine samples, both
glucuronide and sulfate were seen in the bile samples. Surpris-
ingly, 3-APB was also detected in the unconjugated form in the
bile samples. Urine and bile samples were further analyzed for
the presence of the hydroxylated form of 3-APB and benzylace-
tone (fig. 1), which could result from oxidation of 3-APB, but
neither of these compounds could be detected in any of the
samples.
Pharmacodynamics. The changes in the cardiovascular param-
eters (heart rate and mean arterial pressure) produced by labetalol
administration are shown in fig. 7 (A and B). The hypotension
induced by labetalol was accompanied by the development of
transient, but significant, tachycardia. Maximum changes were
seen at 2 hr following drug administration, and control values
were reached by 6 hr. Figure 7C shows the significant increase
in femoral blood flow following labetalol administration. Fem-
oral arterial and venous blood gas changes induced by labetalol
are shown in fig. 8. The marginal but significant decrease in pH
and the more conspicuous decline in base excess suggests the
development of metabolic acidosis over the first 6 hr following
labetalol administration. The mean blood base excess value at 3
hr, which represents the maximum change, shows a decrease
LABETALOL IN ADULT SHEEP
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(A) Heart rate; (B) mean arterial pressure; and (C) femoral blood flow.
Asterisks indicate significant difference from control values.
from mean control value by 3.8 mE.q/liter in the arterial and by
4.7 mEq/liter in the venous blood. Significant changes were also
seen in arterial pCO2, which showed a maximum decrease of
13.9 ± 2.3% and venous p02, which increased by 52.4 ± 6.8%.
Whereas a trend toward an increase was seen in both arterial and
venous oxygen contents, only the latter was significant (fig. 9).
Labetalol also causes significant hyperglycemia and lactic aci-
dosis (fig. 10). The net uptake/output of labetalol, glucose, and
lactic acid by the hind limb was calculated from the respective
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FIG. 8. Effect oflabetalol on blood gas parameters (mean ± SEM).
Asterisks denote significant difference from control values.
using the Fick principle, i.e. [(Ca,thaI Cvenous) . flow], and the
results are shown in fig. 1 1. There was a marked and significant
uptake of labetalol in the initial 15 mm after drug injection,
which however decreases rapidly and beyond 2 hr, there was no
significant uptake or release. There was also net uptake of glucose

















150 \I I I IQ.Q#{176}o -
I i ‘ I
c: 11
100


















































































FIG. 9. Effect oflabetalol on oxygen homeostasis (mean ± SEM).
(A) Arterial and venous oxygen content. (B) Net oxygen uptake by the
hind limb. Asterisks denote significant difference from control values.
over the initial 4 hr, after which there was a reversal of flux. In
contrast, the venous lactic acid concentrations were consistently
higher than or equal to that in the artery (fig. 10), so that there
was sustained lactate release from the hind limb over 12 hr. The
total amount of lactate released was calculated as the AUC of
the lactate output curve and averaged 6.25 ± 1.35 g (0.07 ±
0.015 mol). The net uptake of oxygen (calculated using the Fick
principle as previously described) before and after labetalol ad-
ministration are shown in fig. 9. A significant increase in oxygen
consumption by the hind limb was observed.
Discussion
The primary objectives of this study were to assess the contri-
bution of skeletal muscle and other carcass components to the
lactic acidosis observed following labetalol administration (2)
and to explore the possibility of involvement of active metabo-
lite(s) in the mediation of labetalol-induced metabolic effects.
The adult nonpregnant sheep was chosen as the experimental
model because the initial observations on the metabolic effects
oflabetalol were made in pregnant sheep.
The total body clearance, apparent terminal elimination half-








FIG. 10. Effect oflabetalol on arterial and venous blood glucose and
lactic acid concentrations (mean ± SEM).
Asterisks denote significant difference from control values.
intravenous administration in adult nonpregnant sheep (29.00 ±
2.67 ml/min/kg, 2.4 1 ± 0.03 hr, and 3.22 ± 0.3 1 liter/kg,
respectively) were not different from the corresponding estimates
(30.08 ± 3.83 ml/min/kg, 2.79 ± 0.66 hr, and 3.02 ± 0. 18 liter/
kg) that we have previously obtained in pregnant sheep (2),
suggesting that pregnancy does not alter the pharmacokinetics of
labetalol in sheep. Similar conclusions were reached in human
studies as well (10). Also, the estimates of pharmacokinetic
parameters obtained in this study are similar to the reported
values in normotensive nonpregnant women (mean total body
clearance was 33.8 ml/min/kg and terminal elimination half-life
was 2. 1 hr) (10). The percentage ofthe dose excreted in the urine
as unchanged drug was less than 2%, which is similar to that
reported in humans (0-5%) (1 1). Significant biliary excretion of
the unchanged drug was also seen (fig. 4), and the biliary concen-
trations were consistently higher than the corresponding concen-
trations in plasma, suggesting the involvement of an active
transport mechanism.
Glucuronidation oflabetalol at both the phenolic and second-
ary hydroxy groups has been reported (1 1, 12). The results from
enzyme hydrolysis of urine and bile samples in this study show
that labetalol undergoes significant glucuronidation in the sheep
(1 1 .5%) and the cumulative amount excreted in the urine as
glucuronide(s) was roughly 10-fold larger than the amount cx-
creted as unchanged drug. In sheep, it appears that labetalol also
undergoes sulfation, in contrast to the observations by Martin et










cretion was not made, because continuous collection of bile was
not feasible.
The oxidative metabolism of labetalol has not received much
attention in the past. Recently, Gal et a!. (3), suggested that
labetalol undergoes N-dealkylation (fig. 1) to yield 3-APB and
its hydroxylated derivative, which they identified in urine sam-
ples obtained from patients on labetalol therapy. However, the
quantitative relevance of N-dealkylation or the pharmacody-
namic contribution of the metabolites formed was not clarified.
We developed a sensitive and selective electron impact GC-MSD
assay for the identification and quantitation of 3-APB in biolog-
ical fluids (5). Following positive identification ofthe compound
8 1 1 24 in sheep urine and bile samples, a quantitative assessment of the
excretion of 3-APB in urine was made (fig. 5, A and B). The rate
TIME (h) of excretion of 3-APB in the urine suggests rapid formation of
the metabolite in the first 60 mm following drug administration.
The short apparent elimination half-life of 3-APB (13.5 ± 3.8
mm) prompted us to explore whether this metabolite might
undergo further conjugative/oxidative biotransformation. Both
I  glucuronide and sulfate conjugates of 3-APB were found in the
I   bile, whereas only the glucuronide could be detected in the urine
\T j / samples, which suggests preferential biliary excretion of sulfate
\J   conjugate in the bile, like that observed with labetalol. It seemed
c / surprising that free (unconjugated) 3-APB (molecular weight =
\ I 149) was present in the bile in relatively high concentrations
xc;’ (2OO ng/ml), whereas it remained undetectable in plasma,
particularly since low molecular weight organic cations (92-236
, . , ‘ 1/ . Da) have been shown to undergo insignificant biiary excretion
2 5 8 1 1 24 in several species including sheep ( 13). However, hydrolysis of
TIME (h’t the conjugates in bile in vivo or under the assay conditions, could
V I not be ruled out. No evidence for oxidative metabolism of 3-
APB, including p-hydroxylation, was found.
The significant increase in femoral blood flow along with the
hypotension and delayed onset oftachycardia suggest peripheral
vasodilation and the development of reflex tachycardia. The
occurrence oftachycardia may further suggest that labetalol does
not cause significant 9-antagonism in the sheep. Indeed, the
adrenoreceptor blocking actions of labetalol have been shown to
vary, depending on the experimental situation and the balance
ofautonomic influences involved. Hypotension and reflex tachy-
cardia with no significant change in stroke volume were observed
in conscious, chronically instrumented dogs, whereas decreases
in myocardial contractility and heart rate were seen in anesthe-
2 3 4 5 tized dogs following intravenous labetalol (14). The exact mech-
anism involved in peripheral vasodilation [i.e. a-receptor block-




FIG. 1 1 . Changes in arteriovenousfiuxesfoiowing labeta/ol
administration (mean ± SEM).
Positive values indicate net uptake and negative values indicate net
release from the hind limb. Asterisks denote significant difference from
control values.
differences may be species-related and also dependent on the
enzyme preparations used for conjugate hydrolysis. In contrast
to the extent of glucuronidation, sulfate conjugation was quan-
titatively much less significant (1.5%). In two ofthe animals, the
sulfate conjugates could not be detected in the urine. Both the
glucuronide and sulfate conjugates were excreted in the bile and
the glucuronide/sulfate concentration ratio in the bile was be-
tween 0.5-2.0 while it was -8-10 in urine, suggesting preferential
biliary sulfate excretion. Quantitative assessment of biliary cx-
low)] remains to be studied.
The significant metabolic effects observed following labetalol
administration include hyperglycemia, lactic acidosis, a fall in
arterial pCO2, rise in femoral vein oxygen tension (p02), and
content and an increase in hind limb oxygen consumption. The
decrease in arterial pCO2 was probably due to acidemia-induced
hyperventilation, whereas increase in venous oxygen content was
likely caused by the increased femoral blood flow. Similar met-
abolic effects were observed in our previous study in pregnant
sheep (2), suggesting that pregnancy does not significantly alter
the metabolic outcome of labetalol administration. The initial
hind limb uptake oflabetalol (fig. 1 1) is probably a distribution
phenomenon. The increase in hind limb oxygen uptake suggests
labetalol induced rise in the metabolic rate in carcass compo-
nents. Initial net uptake of glucose may suggest increased con-
sumption of glucose by the hind limb carcass, whereas the
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reversal of flux may be due to glycogenolysis and sparing of
glucose. The consistent and substantial net output oflactate from
the hind limb underlines the significant role played by the skeletal
muscles and other carcass components in the lactic acidosis
induced by labetalol. The hind limb lactate output data can be
extrapolated to the entire carcass based on carcass weight and
the fraction of the carcass weight represented by the hind limb.
In sheep, each hind leg constitutes about 15% ofthe total carcass
weight, which in turn is roughly 50% of the whole body weight
(15). Assuming that the lactate homeostasis within the carcass is
homogenous, the net lactate output from the carcass will be
approximately 41 g (0.46 mol) or 0. 1 1 g/ 100 g of carcass. The
total amount of lactate produced can also be calculated as the
product ofartenal lactate AUC and the clearance value for lactate
in sheep, based on principles ofelimination kinetics (16). Lactate
kinetics in nonpregnant sheep has been studied by Reilly and
Chandrasena (17), 1978, following infusion or [‘4C]lactate to
steady-state. The metabolic clearance of lactate, calculated from
the data provided in their study, is approximately 1.8 ml/min/
kg, so that the net lactate production in this study following
labetalol administration amounts to about 22 g (0.24 mol). This
calculation assumes that the metabolic clearance of lactate is
independent of the concentration of lactate (i.e. linearity in
lactate kinetics). While both the estimates have several assump-
tions and extrapolations involved in their calculations, it would
nonetheless appear that the lactate output from the carcass
almost fully accounts for the elevation in lactate concentration
seen following labetalol administration. It is possible that the
glucose and lactate homeostasis across the hindlimb are interre-
lated, but studies with radiolabeled tracer substrates would be
required to assess this.
The exact mechanism involved in the metabolic effects in-
duced by labetalol are not clear. But there are reasons to suspect
the involvement of active metabolite(s) of labetalol. First, we
have previously reported that the lactic acidosis in the fetal lamb
was much more pronounced than that in the mother, despite
marginal fetal exposure to maternal labetalol (2). Second, the
metabolic effects in both pregnant and nonpregnant sheep sug-
gest potent 3-agonist activity. The identification of 3-APB in the
urine and bile samples is particularly significant because of the
close structural similarity of 3-APB to d-amphetamine (fig. 1), a
potent central stimulant. Not much is known about the phar-
macological effects of 3-APB, but it appears that in terms of
sympathomimetic activity, this compound is at least as potent
as d-amphetamine (18). The pharmacology and toxicology of d-
amphetamine are well documented and in particular, its meta-
bolic effects in both animals and humans following lethal doses
have been reported (19, 20). The toxicity of d-amphetamine had
been attributed to the development of a generalized hypermeta-
bolic state, which includes hyperventilation, transient hypergly-
cemia, lactic acidosis, increased skeletal muscle blood flow, and
increased oxygen consumption, changes which were observed in
this study following labetalol administration. Further, coadmin-
istration of propranolol offered protection against acute d-am-
phetamine intoxication (2 1), which suggests the involvement of
fl-agonism in the amphetamine-induced metabolic effects. The
systemic concentrations of d-amphetamine that were associated
with these effects are not clear, but the peak plasma concentra-
tions observed following therapeutic doses of d-amphetamine
(15-25 mg) in humans are reported to be in the range of 1-50
ng/ml (22, 23). This along with an equal or higher potency of 3-
APB (18) may suggest that 3-APB could be pharmacologically
active at doses that do not result in detectable plasma concentra-
tions. Further experiments involving direct administration of 3-
APB will be necessary to elucidate clearly the contribution of
this metabolite toward the pharmacodynamics of labetalol.
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